Dystrophic Cutaneous Calcification and Metaplastic Bone Formation due to Long Term Bisphosphonate Use in Breast Cancer. (15th July 2013)

• Record Type: Journal Article
• Authors: Tatlı, Ali Murat; Gunduz, Seyda; Göksu, Sema Sezgin; Arslan, Deniz; Uysal, Mukremin; Başsorgun, Cumhur İbrahim; Coşkun, Hasan Şenol
• Other Names: Jones D. V. Academic Editor.; Mauri F. A. Academic Editor.; Mayordomo J. I. Academic Editor.; Reyes C. V. Academic Editor.
• Is Part Of: Case reports in oncological medicine. Volume 2013(2013)
• Publication Date: 2013-07-15
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Oncology -- Case studies -- Periodicals; Neoplasms; Oncology; Tumors; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.994
• DOI: 10.1155/2013/871917
• Languages: English
• ISSNs: 2090-6706

Abstract

Abstract : Bisphosphonates are widely used in the treatment of breast cancer with bone metastases. We report a case of a female with breast cancer presented with a rash around a previous mastectomy site and a discharge lesion on her right chest wall in August 2010. Biopsy of the lesion showed dystrophic calcification and metaplastic bone formation. The patient's history revealed a long term use of zoledronic acid for the treatment of breast cancer with bone metastasis. We stopped the treatment since we believed that the cutaneous dystrophic calcification could be associated with her long term bisphosphonate therapy. Adverse cutaneous events with bisphosphonates are very rare, and dystrophic calcification has not been reported previously. The dystrophic calcification and metaplastic bone formation in this patient are thought to be due to long term bisphosphonate usage.